Sept 18 (Reuters) -

BioAge Labs, an obesity therapy-focused company that has

also collaborated with Eli Lilly ( LLY ), said on Wednesday it

was seeking a valuation of as much as $587 million in its

initial public offering in the United States

.

Healthcare firms have done comparatively well in an

otherwise subdued U.S. IPO market in 2024, which was touted by

analysts to be a comeback year for public offerings.

BioAge will list its shares on the Nasdaq under the

symbol "BIOA."

Goldman Sachs, Morgan Stanley, Jefferies and Citigroup

are the underwriters for the offering.